Form 4 for CRL Charles River Laboratories
Accepted 2022-02-01 00:00:00 ET · period of report 2022-01-28 · accession 0001127602-22-002801 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-01 | 2022-01-28 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | F - Tax | $312.24 | -4,570 | 21.8K | -17% | -$1.43M | |
| 2022-02-01 | 2022-01-28 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | A - Grant | $0.00 | +11.3K | 26.4K | +75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-28 | F | D | 4,570 | $312.24 | 21,825 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-28 | A | A | 11,344 | $0.00 | 26,395 | D | — | — | (F1) Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 22, 2019. |